





Toulouse, March 11th2021

STUDY 20-2799
REPORT N°21-1657

**EVALUATION OF THE VIRUCIDAL ACTIVITY OF NON-POROUS SURFACES
AGAINST HUMAN CORONAVIRUS 229 E ACCORDING TO THE METHODOLOGY
OF STANDARD ISO 21702 (MAY 2019)**

Client **MICROBECLEAN**
1 bis rue des Longrais
35520 LA-CHAPELLE-DES-FOUGERETZ

Test laboratory **FONDEREPHAR**
Faculté des Sciences Pharmaceutiques
35 Chemin des Maraîchers
31062 TOULOUSE cedex 9
FRANCE

| | |
|---|--|
| <p>Dr Laïla HADDIOUI Study Manager</p>  | <p>Dr Jocelyne BACARIA Quality Manager</p>  |
|---|--|

I - TEST LABORATORY IDENTIFICATION

FONDEREPHAR
 Faculté des Sciences Pharmaceutiques
 35 Chemin des Maraîchers
 31062 TOULOUSE cedex 9
 FRANCE

II -SAMPLE IDENTIFICATION

| | |
|----------------------|---|
| - Product name: | MICROBECARE 70-2 treated plastic supports |
| - Batch: | 48 MICA08/0141 |
| - Date of receipt: | November/06/2020 |
| - Internal code: | 20-2799-1 |
| - Product name: | Untreated plastic supports |
| - Batch: | Not communicated |
| - Date of receipt: | November/06/2020 |
| - Internal code: | 20-2799-2 |
| - Supplier: | MICROBECLEAN |
| - Period of testing: | March 2021 |

III - TEST METHOD**III-1 VIRUS**

| | |
|------------------------|-------------------------|
| Name: | HCOV 229 E |
| Origin: | ATCC |
| Reference: | VR-740 |
| Supplier batch number: | 58505270 |
| Internal batch number: | SS-2-210920 (Passage 2) |

II-2- Recipient cells

| | |
|------------------------|-------------------------|
| Name: | VERO |
| Origin: | ATCC |
| Reference: | CCL-81 |
| Supplier batch number: | 3372621 |
| Internal batch number: | WCB-090708 (Passage 44) |

IV -TEST CONDITIONS

- Contact time: 2 hours and 6 hours
 - Assay temperature: 25°C ± 1°C

V- TEST METHOD

V-1 Control of cytotoxicity

2.5 ml of neutralizing medium are added to 3 untreated and 3 treated samples. The samples are washed 4 times with the neutralizing medium.

A ten-fold serial dilution is made to check the absence of cellular cytotoxicity.

V-2 Control of the sensitivity of the cells to the virus and stopping the antiviral activity

2.5 ml of neutralizing medium are added to 3 untreated and 3 treated samples.

The samples are washed 4 times with the neutralizing medium. Then 1.98 ml of recovery medium are mixed with 20 μ l of the virus suspension prepared at a concentration of 4 to 6 $\cdot 10^6$ TCID₅₀/ml. After 30 min of 25°C incubation, tubs with virus solution are maintained in ice before titration.

V-3 Contact virus/surface

Each sample with a surface area of 5 cm x 5 cm (control and test samples) is placed in a sterile glass Petri dish.

- 400 μ l of the viral suspension are deposited on each surface and spread over 16 cm² using a 4 x 4 cm film to reduce desiccation of the inoculum.

V-4 Recovery of the viral film

After incubation, 3.6 ml of a neutralizing solution (frozen culture medium) are added to the samples in order to recover viable viruses.

The titration of the remaining viable viruses is then carried out immediately.

V-5 Viral Titer

The titration technique is indicated in the standard NF EN 14476 + A2 (July 2019).

A ten-fold serial dilution of the viral suspensions is made in the cell culture medium in neutral glass tubes in order to limit the phenomena of virus adsorption on the surfaces.

Titration is performed on 96-well microplates. Each dilution is transfer in 8 wells.

V-6 Viral load calculation

The assay is performed by the microplate method of suspension cells. The cytopathic effect is determined at least 4 days of culture.

The number of infectious units is estimated with the SPEARMAN-KÄRBER method by calculating the negative logarithm of the 50% limit point (lgTCID₅₀) using the following formula:

$\lg\text{TCID}_{50} = \text{Negative logarithm of the highest concentration of virus used} - [(\text{Sum of \% assigned to each dilution}/100 - 0.5) \times (\lg \text{ of dilution})]$

The following tests are carried out 3 times.

VI- RESULTS

VI-1 Validation

VI-1-1 Control of cytotoxicity

No cytotoxicity was observed on the cells after contact of the culture medium with treated and untreated samples.

VI-1-2 Control of the sensitivity of cells to viruses and cessation of virucidal activity

The difference between the average titers (lg TCID₅₀) of the neutralizing solution controls of and the sensitivity titers average of the treated and untreated surfaces must be less than or equal to 0.5 lg.

Neutralizing solution control

- Control 1 : lg TCID₅₀ = 4.00
- Control 2 : lg TCID₅₀ = 4.13
- Control 3 : lg TCID₅₀ = 3.88

lg TCID₅₀ neutralizing solution control average = 4.0

Control Sensitivity of untreated surfaces

- Control 1 : lg TCID₅₀ = 3.75
- Control 2 : lg TCID₅₀ = 4.00
- Control 3 : lg TCID₅₀ = 3.88

lg TCID₅₀ Sensitivity of untreated surfaces average = 3.88

Titer neutralizing solution average - Sensitivity of untreated surfaces average = 0.12

Difference \leq 0.5 lg (verification valid)

Test Sensitivity and cytotoxicity

- Control 1 : lg TCID₅₀ = 3.88
- Control 2 : lg TCID₅₀ = 3.63
- Control 3 : lg TCID₅₀ = 3.88

Average lg TCID₅₀ Control Sensitivity = 3.80

Titer neutralizing solution average - Sensitivity of treated surfaces average = 0.20

Difference \leq 0.5 lg (verification valid)

VI-1-3 T0 controls

- Control 1 : lg TCID₅₀ = 5.88
- Control 2 : lg TCID₅₀ = 5.75
- Control 3 : lg TCID₅₀ = 5.75
-

lg TCID₅₀ T0 average = 5.79

Maximum viral title - Minimum viral title = 0.02
Average of the 3 viral titles

The titer (lg DICT₅₀) of the 3 tests at T0 must be homogeneous
Maximum viral titer - Minimum viral titer / Average of the 3 viral titer ≤ 0,2.

TCID₅₀ average /ml = 6.17.10⁶

Average TCID₅₀ /ml = 10^{average log₁₀ DCICT₅₀} × 10

Infectivity titer (TCID₅₀/cm²) = $\frac{\text{TCID}_{50}/\text{ml} * \text{Volume de récupération (4ml)}}{\text{Surface (16 cm}^2\text{)}} = 2.06 \cdot 10^6$

Infectivity titer at T0 (TCID₅₀/cm²) must be between 8.94 10⁵ and 4.46 10⁶

VI-2 Tests**VI-2-1 Contact time 2 hours****VI-2-1-1 Control T2 h**

- Control 1 : lg TCID₅₀ = 5.63
- Control 2 : lg TCID₅₀ = 5.25
- Control 3 : lg TCID₅₀ = 5.63

lg TCID₅₀ T2 average = 5.50

Average TCID₅₀ /ml = 3.16 10⁶

Average TCID₅₀ /ml = 10^{average log₁₀ DCICT₅₀} × 10

Infectivity titer (TCID₅₀/cm²) = $\frac{\text{TCID}_{50}/\text{ml} * \text{Recovery volume (4ml)}}{\text{Surface (16 cm}^2\text{)}} = 7.90 \cdot 10^5$

Infectivity titer at contact time 2 hours (TCID₅₀/cm²) must be greater than 2.21 10³

VI-2-1-2 Surface test MICROBECARE 70-2 T2 h

- Essai 1 : lg TCID₅₀ = 3.75
- Essai 2 : lg TCID₅₀ = 3.38
- Essai 3 : lg TCID₅₀ = 3.50

lg TCID₅₀ T2h average = 3.50

R = lg TCID₅₀ control 2 hours average - lg TCID₅₀ Test 2 hours average = 1.96 lg

VI-2-2 Contact time 6 hours**VI-2-2-1 Control T6 h**

- Control 1 : lg TCID₅₀ = 5.25
- Control 2 : lg TCID₅₀ = 5.38
- Control 3 : lg TCID₅₀ = 5.50

lg TCID₅₀ T6 h average = 5.38

Average TCID₅₀ /ml = 2.40 10⁶

Average TCID₅₀ /ml = 10^{average log₁₀ DCICT₅₀} × 10

Infectivity titer (TCID₅₀/cm²) = $\frac{\text{TCID}_{50}/\text{ml} \times \text{Recovery volume (4ml)}}{\text{Surface (16 cm}^2\text{)}} = 6.0 \cdot 10^6$

Infectivity titer at contact time 6 hours (TCID₅₀/cm²) must be greater than 2.21 10³

VI-2-2-2 Surface test MICROBECARE 70-2 T6 h

- Essai 1 : lg TCID₅₀ = 2.63
- Essai 2 : lg TCID₅₀ = 2.75
- Essai 3 : lg TCID₅₀ = 2.75

lg TCID₅₀ T6 average = 2.71

R = lg TCID₅₀ control 6 hours average - lg TCID₅₀ Test 6 hours average = 2.67 lg

VII-CONCLUSION

According to the methodology of the ISO 21702 standard (May 2019), contact of the surface MICROBECARE 70-2 (Batch N°48MICA08/0141) with the strain of Human coronavirus 229 E induces:

- a reduction of the viral titer of 1.96 lg at the contact time 2 hours.
- a reduction of the viral titer of 2.67 lg at the contact time 6 hours.

The treatment of the surface MICROBECARE 70-2 (Batch N°48MICA08/0141) induces a reduction of the viral load of 98.90 % at the contact time 2 hours and of 99.79% at the contact time 6 hours.